Menu HOME > SOLUTIONS > INFORMATICS > MEDICAL IMAGING > THERAPEUTIC EXPERTISE > ONCOLOGY IMAGING EXPERTISE > CRITERIA EXPERIENCE > 2007 IWG-NHL > KEY TOPICS: 2007 IWG-NHL ASSESSMENT CRITERIA > TARGET SITES OF DISEASE OFFERED BY KEY TOPICS: IWCLL 2008 KEY TOPICS: 2007 IWG-NHL ASSESSMENT CRITERIA INCORPORATES KEY TOPICS: 2007 IWG-NHL ASSESSMENT CRITERIA SOLUTIONS DEFINITIONS USABLE CRITERIA TO EVALUATE TARGET SITES OF DISEASE NON-TARGET SITES OF DISEASE ORGANOMEGALY NEW LESIONS BONE MARROW OTHER LABORATORY VALUES AND SYMPTOMS INCORPORATION OF FDG-PET DEFINING NORMAL, ABNORMAL AND MEASURABLE PROBLEM WITH CRU Up to six (6) nodes should be selected and followed as measurable sites (Target Nodes). Target nodes should be categorized into Large Nodes and Small Nodes. Large Nodes are those nodes and nodal masses >1.5 cm in longest diameter at baseline regardless of short diameter Small Nodes are those nodes and nodal masses >1.0 - ≤1.5 cm in longest diameter and >1.0 cm in short diameter at baseline. Measurable (Target) extranodal lesions should also be followed and are grouped into one size category. Target extranodal lesions must measure >1.0 x 1.0 cm. Target extranodal lesions include splenic and hepatic nodules as well as any nodules outside of the spleen and liver which are considered manifestations of disease. Although the 2007 IWG-NHL publication does not make a specific recommendation on the number of measurable extranodal sites to be followed, in concordance with the guidance for nodal disease, Perceptive Informatics recommends that (until further scientific validation suggests otherwise), six (6) extranodal lesions should also be followed. DEFINITIONS USABLE CRITERIA TO EVALUATE NON-TARGET SITES OF DISEASE ORGANOMEGALY NEW LESIONS BONE MARROW OTHER LABORATORY VALUES AND SYMPTOMS INCORPORATION OF FDG-PET DEFINING NORMAL, ABNORMAL AND MEASURABLE PROBLEM WITH CRU DEFINITIONS USABLE CRITERIA TO EVALUATE NON-TARGET SITES OF DISEASE ORGANOMEGALY NEW LESIONS BONE MARROW OTHER LABORATORY VALUES AND SYMPTOMS INCORPORATION OF FDG-PET DEFINING NORMAL, ABNORMAL AND MEASURABLE PROBLEM WITH CRU LINKEDIN UPDATES VIEW PROFILE Read about “growing more diverse” by @PAREXEL’s Ulf Schneider https://t.co/tuEDlB38wA #diversity https://t.co/mAD80nlSkq Explore trends from #DIA2016 highlighted by @PAREXEL’s Roland Andersson. https://t.co/Mgpyfz5fho #ASIA calling! Join our webinar Biostatistician #careers at @PAREXEL Asia Aug 11: https://t.co/swFUZgmhk0 #relocation #US #biostat CAREERS AT PAREXEL® If you are inspired to make a difference in the world, we can help you make it possible. Search positions worldwide PAREXEL International Corp. +1 781 487 9900 195 West Street Waltham, MA 02451 ABOUT PAREXEL® NEWS & EVENTS INVESTORS VOLUNTEER CONTACT CLIENT LOGIN LIQUENT® CLINICAL TRIAL INVESTIGATOR SITE MAP TERMS OF SERVICE PRIVACY POLICY Copyright ©2000-2016 PAREXEL International Corporation.